Entrada Therapeutics Future Growth
Future criteria checks 1/6
Entrada Therapeutics's earnings are forecast to decline at 1.5% per annum while its annual revenue is expected to grow at 10.4% per year. EPS is expected to decline by 0.1% per annum.
Key information
-1.5%
Earnings growth rate
-0.1%
EPS growth rate
| Biotechs earnings growth | 20.6% |
| Revenue growth rate | 10.4% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 26 Mar 2024 |
Recent future growth updates
Recent updates
These Analysts Just Made A Massive Downgrade To Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) EPS Forecasts
Mar 19
This Just In: Analysts Are Boosting Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) Outlook for Next Year
Nov 09Need To Know: Analysts Are Much More Bullish On Entrada Therapeutics, Inc. (NASDAQ:TRDA)
May 26Earnings Miss: Entrada Therapeutics, Inc. Missed EPS And Analysts Are Revising Their Forecasts
May 14Will Entrada Therapeutics (NASDAQ:TRDA) Spend Its Cash Wisely?
Mar 08We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate
Sep 11Entrada Therapeutics GAAP EPS of -$0.74 misses by $0.02
Aug 11We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate
May 28We Think Entrada Therapeutics (NASDAQ:TRDA) Can Afford To Drive Business Growth
Jan 31Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 31 | -164 | N/A | -107 | 4 |
| 12/31/2025 | 29 | -139 | N/A | -106 | 4 |
| 12/31/2024 | 62 | -82 | N/A | 13 | 5 |
| 12/31/2023 | 129 | -7 | 134 | 140 | N/A |
| 9/30/2023 | 87 | -22 | 111 | 117 | N/A |
| 6/30/2023 | 43 | -82 | 109 | 114 | N/A |
| 3/31/2023 | 25 | -80 | 127 | 131 | N/A |
| 12/31/2022 | N/A | -95 | -97 | -94 | N/A |
| 9/30/2022 | N/A | -88 | -91 | -87 | N/A |
| 6/30/2022 | N/A | -78 | -77 | -74 | N/A |
| 3/31/2022 | N/A | -64 | -68 | -64 | N/A |
| 12/31/2021 | N/A | -51 | -55 | -51 | N/A |
| 9/30/2021 | N/A | -41 | -42 | -37 | N/A |
| 6/30/2021 | N/A | -34 | -33 | -29 | N/A |
| 3/31/2021 | N/A | -29 | -30 | -27 | N/A |
| 12/31/2020 | N/A | -27 | -28 | -26 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TRDA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TRDA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TRDA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: TRDA's revenue (10.4% per year) is forecast to grow faster than the US market (8.1% per year).
High Growth Revenue: TRDA's revenue (10.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if TRDA's Return on Equity is forecast to be high in 3 years time